Trajectory Analysis of Orthostatic Hypotension in Parkinson’s Disease: Results From Parkinson’s Progression Markers Initiative Cohort

Kui Chen†, Kangshuai Du†, Yichen Zhao, Yongzhe Gu and Yanxin Zhao*

Department of Neurology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China

Background: Orthostatic hypotension (OH) in Parkinson’s disease (PD) can lead to falls, impair quality of life, and increase mortality. A trajectory analysis of OH could be useful to predict and prevent the hypotension incidence early.

Methods: The longitudinal data of 660 patients with PD with disease duration up to 12 years were extracted from an integrated PD database. We used latent class mixed modeling (LCMM) to identify patient subgroups, demonstrating trajectories of changes in orthostatic blood pressure (BP) over time. The optimal number of subgroups was selected by several criteria including the Bayesian Information Criterion. Baseline information comparison between groups and backward stepwise logistic regression were conducted to define the distinguishing characteristics of these subgroups and to investigate the predictors for BP trajectory.

Results: We identified three trajectories for each orthostatic change of systolic blood pressure ($\Delta$SBP), namely, Class 1 (i.e., the increasing class) consisted of 18 participants with low $\Delta$SBP that increased continuously during the follow-up; Class 2 (i.e., the low-stable class) consisted of 610 participants with low $\Delta$SBP that remained low throughout the follow-up; and Class 3 (i.e., the high-stable class) consisted of 32 participants with high $\Delta$SBP at baseline that was relatively stable throughout the follow-up. Several parameters differed among subgroups, but only male sex [odds ratio (OR) = 4.687, 95% confidence interval (CI) = 1.024–21.459], lower supine diastolic blood pressure (DBP) (OR = 0.934, 95% CI = 0.876–0.996), and lower level of total protein at baseline (OR = 0.812, 95% CI = 0.700–0.941) were significant predictors of an increasing $\Delta$SBP trajectory.

Conclusion: This study provides new information on the longitudinal development of $\Delta$SBP in patients with PD with distinct trajectories of rapidly increasing, low-stable, and high-stable class. The parameters such as male sex, lower supine DBP, and lower total proteins help to identify the rapidly increasing class.

Keywords: orthostatic hypotension, Parkinson’s disease, blood pressure, trajectory analysis, latent class mixed modeling
INTRODUCTION

Orthostatic hypotension (OH), a sustained fall in blood pressure (BP) upon standing, is among the most debilitating manifestations of autonomic dysfunction in Parkinson’s disease (PD). Classical OH is defined as a sustained reduction of at least 20 mmHg of systolic blood pressure (SBP) or 10 mmHg of diastolic blood pressure (DBP) within 3 min of standing or the head-up tilt-table testing (Freeman et al., 2011). Currently, the reported incidence of PD-OH varies from 11.1 to 51.6% (Hommel et al., 2016; Li et al., 2019; Quarracino et al., 2020). The prevalence of OH in PD increases with age and disease duration (Li et al., 2019). OH can impair the blood supply to organs above the heart, such as the brain, resulting in symptoms related to tissue hypoperfusion. The characteristic symptoms include lightheadedness, vertigo, presyncope, and syncope. Symptomatic OH increases the likelihood of falls and has been proven as an independent risk factor of mortality (Masaki et al., 1998; McDonald et al., 2017). There is a significant linear association between the change in systolic BP from supine position to standing and the 4-year mortality rates (Masaki et al., 1998). Furthermore, daily activities and quality of life of patients with PD-OH are significantly compromised relative to patients with PD without OH (Li et al., 2019).

Several confounding variables may influence the extent to which orthostatic BP falls, such as gender, age, hydration, blood glucose, deconditioning, and anemia (Freeman et al., 2011; Perez-Lloret et al., 2012; Li et al., 2019). OH is also independently associated with PD-related parameters, such as the PD phenotype of postural instability and gait disorders (PIGD), lower Mini-Mental State Examination score, longer follow-up time, and higher levodopa equivalent dosage (Hiorth et al., 2019).

However, there have been few studies investigating the longitudinal orthostatic BP changes of patients with PD. BP trajectory could facilitate the prediction of hypotension and hence may be useful in OH prevention. This study was based on the data from the Parkinson’s Progression Markers Initiative (PPMI). The aim of this study was to identify latent subgroups of orthostatic BP trajectories and to investigate the associated factors that influence the different trajectory types. The analysis of orthostatic BP change was based on SBP because the systolic criteria seem to be sufficient to identify 95% of subjects with OH (Fedorowski et al., 2017). In addition, the absolute magnitude of changes in SBP is larger and easier to measure than DBP and as such is more accurate.

MATERIALS AND METHODS

Study Design and Participants

We used data from PPMI, which is an observational, longitudinal, and multicenter study designed to establish the clinical, imaging, and biosample data to define biomarkers of PD progression. The methodology and details of the study assessments are available on the PPMI website. The data were accessed on August 1, 2020. The patients with PD with available BP measurements at two or more visits during a 12-year duration of disease were included. A duration of 12 years was chosen as the upper limit because the majority of participants were patients with de novo PD at baseline. Data volumes decrease significantly at longer durations, reducing the reliability of results. From the relationship between disease duration and the number of patients whose BP was measured (Supplementary Figure 1), an upper limit of 12-year duration contained more than 95% BP data (96.43%). Any patient whose primary diagnosis of PD was changed to any other disease during the follow-up was excluded. Each participating PPMI site received ethical approval before study initiation and obtained written informed consent from all participants.

Clinical Assessments

Parkinson’s disease-related signs and symptoms were assessed with the Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) (Goetz et al., 2008) every year. The motor function was measured with the MDS-UPDRS part 3 (MDS-UPDRS-III) in the off-state. Motor phenotypes were determined as tremor-dominant (TD) phenotype, PIGD phenotype, or indeterminate phenotype, following the classification algorithm proposed by Stedebbek et al. (2013). In brief, the PIGD measure includes the five items, namely, freezing, walking and balance in MDS-UPDRS part 2 (MDS-UPDRS-II), gait, freezing of gait, and postural stability in MDS-UPDRS-III; the tremor measure includes the 11 items of tremor in MDS-UPDRS-II, postural tremor, kinetic tremor, rest tremor, and rest constancy in MDS-UPDRS-III. The ratio of tremor score to PIGD score was used to define patients with TD (ratio $\geq 1.15$), indeterminate patients ($0.9 < \text{ratio} < 1.15$), and PIGD-dominant patients (ratio $\leq 0.9$). The Hoehn and Yahr staging scale (Hoehn and Yahr, 1967) was used for describing how the symptoms of PD progress. The olfactory impairment was measured by the University of Pennsylvania Smell Identification Test (UPSIT). Global cognitive status was assessed using the Montreal Cognitive Assessment. Rapid eye movement sleep behavior disorder (RBD) was screened using the RBD screening questionnaire (RBDSQ). The dosage of PD medications taken was collected and converted to a levodopa equivalent daily dose (LED) using the methods described by Tomlinson et al. (2010).

Vital Signs, Weight, and Height Measurements

Blood pressure (i.e., supine and standing) was measured at every visit. The supine BP was determined after 1–3 min of quiet rest, and the standing pressure was determined after 1–3 min in the standing position. The orthostatic SBP change was calculated as $\Delta$SBP (supine SBP minus standing SBP; note that a positive value represented a drop in SBP with standing). The same was $\Delta$DBP (supine DBP minus standing DBP). Weight and height were collected at the baseline visit and annually or bi-annually according to the visit schedule.

Clinical Laboratory Tests

Routine clinical laboratory tests consisting of complete blood count and metabolic panel were performed at screening and annually. A central laboratory was implemented to guarantee...
identical analysis methods, consistent normal ranges, and, thus, common interpretation of laboratory changes. In this research, laboratory parameters possibly related to OH were extracted from all test results, including red blood cell count, hematocrit, hemoglobin, serum glucose, serum sodium, serum potassium, serum chloride, total protein, albumin, creatinine, urea nitrogen, and serum uric acid.

Statistical Analysis
Continuous variables were expressed as the median and interquartile range (IQR), due to the non-normal data distributions evident upon graphical inspection and application of the Shapiro-Wilk test. Categorical variables were expressed as frequencies and percentages.

We used latent class mixed modeling (LCMM) to model longitudinal ΔSBP. LCMM is a statistical approach that identifies the heterogeneity between patients by classifying them into unobserved subgroups (i.e., latent classes). The time from disease onset (years) was used as the time indicator. The best model was chosen according to (1) Bayesian information criterion (BIC), (2) high mean posterior probability greater than 0.7, (3) sufficient group sizes, and (4) the clinical significance of the models (Louvet et al., 2009; Nagin and Odgers, 2010). To maintain an adequate sample size and clinical significance of each group, we performed models with two to five classes in the current study.

Comparisons of baseline information among subgroups were performed using the Kruskal-Wallis test for quantitative variables and the chi-square test for categorical variables. In the case of significant results, pairwise comparisons were performed, and a Bonferroni correction was applied. Variables with significant differences were further analyzed in the backward stepwise logistic regression of the latent classes.

All data analyses were performed using the SPSS software version 26 (IBM Corp., Armonk, NY, United States) and R software version 4.0.3 with the package "LCMM" for the latent class analysis. A p-value of less than 0.05 was considered statistically significant.

RESULTS
Demographic and Clinical Characteristics of Participants
A total of 660 participants with available BP at two or more visits during the 12-year duration of disease were included. Characteristics of the study population at the time of entry are presented in Table 1. Continuous variables were expressed as median (i.e., IQR) due to non-normal distribution. The median age at baseline was 63 years (IQR: 55–70), and 58.3% of the population were male. Most patients with PD were newly diagnosed and drug-naive, with a median duration of 2 years (IQR: 1–4) since the symptom onset. Therefore, the majority of patients were within Hoehn and Yahr stage 1 or 2. Based on MDS-UPDRS scores, motor phenotypes were determined as TD (n = 439, 66.5%), PIGD (n = 154, 23.3%), or indeterminate (n = 67, 10.2%). The median of LEDD at baseline was 0 mg (IQR: 0, 405.25). Among all participants, 88 patients (13.4%) presented OH.

| TABLE 1 | Demographical and clinical characteristics of participants. |
|-----------------|-----------------|-----------------|
| Demographics    | Patients (n = 660) | Missing, n   |
| Age, years      | 63 (65.70)       | 0              |
| Male, n (%)     | 385 (58.3%)      | 0              |
| Weight, kg      | 78 (67, 88.9)    | 1              |
| Height, cm      | 170 (164,178)    | 1              |
| BMI             | 26.23 (23.84, 29.67) | 1            |
| PD characteristics |                   |                |
| Duration, years | 2 (1, 4)         | 0              |
| HY              | 2 (1.2)          | 0              |
| MDS-UPDRS-I     | 6 (3.9)          | 3              |
| MDS-UPDRS-II    | 5.5 (3.9)        | 2              |
| MDS-UPDRS-III   | 20 (14.27)       | 0              |
| MDS-UPDRS-IV    | 0 (0.3)          | 426            |
| Subtype         |                   |                |
| TD              | 439 (66.5%)      | 0              |
| PIGD            | 154 (23.3%)      | 0              |
| Indeterminate   | 67 (10.2%)       | 0              |
| UPSIT           | 22 (16.29)       | 11             |
| MOCA            | 27 (25.29)       | 112            |
| RBDSQ           | 3 (2.5)          | 3              |
| Baseline LEDD, mg | 0 (0,405.25)    | 14             |
| Blood pressure  |                   |                |
| Supine SBP, mmHg | 129 (119, 141)  | 1              |
| Supine DBP, mmHg | 78 (70, 84)     | 1              |
| Standing SBP, mmHg | 124 (115, 138.5) | 3            |
| Standing DBP, mmHg | 80 (72, 86)    | 3              |
| ΔSBP, mmHg      | 3 (–3, 10)       | 3              |
| ΔDBP, mmHg      | –2 (–6, 2)       | 3              |
| OH, n (%)       | 88 (13.4%)       | 3              |
| Clinical laboratory assessment | | |
| RBC count, × 10^6/µL | 4.6 (3.45, 4.95) | 155          |
| Hematocrit, %   | 0.41 (0.39, 0.43) | 158          |
| Hemoglobin, g/dl | 142 (134, 150)  | 155           |
| Serum glucose, mg/dl | 5.4 (5, 5.9)   | 151           |
| Serum sodium, mmol/L | 141 (139, 142) | 150           |
| Serum potassium, mmol/L | 4.2 (4, 4.4) | 151           |
| Serum chloride, mmol/L | 103 (101, 104) | 150           |
| Total protein, g/dl | 70 (68, 73)    | 150           |
| Albumin, g/dl   | 41 (40, 43)      | 151           |
| Creatinine, mg/dl | 80 (71, 94)    | 151           |
| Urea nitrogen, mg/dl | 6.1 (5, 7.1)  | 150           |
| Serum uric acid, mg/dl | 303 (250, 357) | 150           |

BMI, body mass index; DBP, diastolic blood pressure; HY, Hoehn and Yahr staging; LEDD, levodopa equivalent daily dose; MOCA, Montreal Cognitive Assessment; OH, orthostatic hypotension; PIGD, postural instability and gait disorders; RBC, red blood cell; RBDSQ, rapid eye movement sleep behavior disorder screening questionnaire; SBP, systolic blood pressure; TD, tremor dominant; MDS-UPDRS, Unified Parkinson’s Disease Rating Scale; UPSIT, University of Pennsylvania Smell Identification Test; ΔDBP, orthostatic DBP change; ΔSBP, orthostatic SBP change. These values represent the medians, with the interquartile range in parentheses or the number of patients, with percentages in parentheses.
Considering that long-term PD medication and hypertension may influence ASBP, we also calculated the average LEDD and prevalence of hypertension during the follow-up. The median of average LEDD was 473.75 mg (IQR: 300.00–713.24), and a total of 232 patients (35.2%) developed hypertension at baseline or during follow-up.

**Latent Class Analysis of Orthostatic Change of Systolic Blood Pressure**

On the basis of longitudinal ASBP, patients were classified into groups using disease duration as the preferred time indicator. **Supplementary Tables 1–3** present the LCMM results of the fitting process. The model of four classes had the lowest BIC; however, there were only three patients (0.45%) in one group of the four classifications. Therefore, the model of three latent classes was regarded as the most appropriate (Figure 1). In this model, Class 1 included 18 participants (2.73%) with low initial ASBP that increased consistently during the follow-up (i.e., increasing class). Class 2 included 610 participants (92.42%) with low initial ASBP that remained low throughout the follow-up (i.e., low-stable class). Class 3 included 32 participants (4.85%) with higher initial ASBP that was relatively stable over time (i.e., high-stable class).

**Comparison of Trajectory Subgroups**

The baseline characteristics of participants in different trajectory subgroups are shown in **Table 2**. BPs at baseline varied significantly among groups as shown in **Figure 1**. In addition, the three classes differed in multiple variables relating to demographics, PD characteristics, and laboratory tests. In comparison with Class 2, participants in Class 1 were overall older, taller, and had a higher proportion of males, lower levels of total protein, and higher levels of serum potassium. Compared with Class 2, participants in Class 3 were older and taller. Moreover, Class 3 demonstrated a higher incidence of hypertension, higher MDS-UPDRS-III scores, poorer olfaction reflected by UPSIT, and more severe REM sleep disorder represented by RBDSQ. It appeared that older, taller males with severe motor and non-motor symptoms, lower levels of total protein, and higher levels of urea nitrogen tended to develop increasing or high-stable ASBP trajectories. However, no significant differences between Class 1 and Class 3 were found except for baseline ASBP and serum potassium.

**Logistic Regression Analysis of Baseline Predictors for Orthostatic Change of Systolic Blood Pressure Trajectory**

Since Class 2 and Class 3 both showed relatively stable trajectories, it was of clinical significance to identify Class 1 with consistently increasing ASBP from the two types. In the regression analysis, Class 2 and Class 3 were collapsed into one agreement group, given their similar flat slopes. Due to the interdependent nature of standing BP, supine BP and orthostatic change of BP, only supine BP and BP changes were included in the regression. Regression results revealed that male (odds ratio (OR) = 4.687, 95% confidence interval (CI) = 1.024–21.459), lower supine DBP (OR = 0.934, 95% CI = 0.876—0.996), and lower level of total protein (OR = 0.812, 95% CI = 0.700–0.941) were significant predictors of an increasing ASBP trajectory, as presented in **Figure 2**. The logistic regression model can be considered reliable since the predicted variability resulted in an area under the curve of 0.817 in the ROC analysis (Supplementary Figure 1).

**DISCUSSION**

We identified subgroups of ASBP trajectory in patients with PD based on a longitudinal analysis of PPMI data. The best fit was identified for a three-class model, reflecting three subgroups of...
the ΔSBP change. Class 1 was characterized by rapidly increasing ΔSBP. Class 2 displayed a lower level of ΔSBP throughout the follow-up, while Class 3 was characterized by a greater ΔSBP at baseline.

Orthostatic hypotension is associated with target organ damage and typically manifests with recurrent syncope and orthostatic intolerance. Previous research has demonstrated that OH increases the risk of falls in patients with PD and is associated with cognitive impairment and greater deterioration in daily living activities, regardless of whether or not OH is symptomatic.

### TABLE 2 | Characteristics of the study population by orthostatic systolic blood pressure change (ΔSBP) trajectory groups.

| Demographics          | Class 1 | Class 2 | Class 3 | p   | Post hoc (Bonferroni adjustment) |
|-----------------------|---------|---------|---------|-----|----------------------------------|
| Age, years            | 69 (64.5, 74) | 63 (55, 70) | 67 (62.25, 71) | 0.001 | 0.027 | 1 | 0.024 |
| Male, n (%)           | 16 (88.9%) | 345 (66.6%) | 24 (75.0%) | 0.003 | <0.05 | > 0.05 | >0.05 |
| Weight, kg            | 80.65 (73.48, 90.70) | 77.6 (67, 88.75) | 79.7 (65.63, 94.1) | 0.442 | – | – | – |
| Height, cm            | 175 (169.5, 180.25) | 170 (163, 178) | 176.5 (168, 181.5) | 0.003 | 0.067 | 1 | 0.023 |
| BMI                    | 25.86 (24.20, 28.26) | 26.28 (23.87, 29.70) | 25.72 (22.90, 29.64) | 0.661 | – | – | – |

### PD characteristics

- **Duration, years**: 2 (1, 3.5) | 2 (1, 4) | 2 (1, 2) | 0.095 | – | – | – |
- **Hy**: 2 (1, 2) | 2 (1, 2) | 2 (2, 2) | 0.114 | – | – | – |
- **MDS-UPDRS-I**: 6 (4, 11) | 5 (3, 9) | 7 (4, 11) | 0.091 | – | – | – |
- **MDS-UPDRS-II**: 8 (5, 9.5) | 5 (3, 9) | 6 (4, 12) | 0.067 | – | – | – |
- **MDS-UPDRS-III**: 20 (15.75, 30.25) | 20 (14, 27) | 25 (19.25, 30.75) | 0.020 | 1 | 0.805 | 0.019 |
- **MDS-UPDRS-IV**: 0 (0, 2.5) | 0 (0, 3) | 1 (0, 3.5) | 0.818 | – | – | – |

### Blood pressure, mmHg

- **Supine SBP**: 134.5 (120.25, 142.75) | 128 (118, 140) | 145.5 (131.5, 150.75) | 0.000 | – | 0.175 | <0.001 |
- **Standing SBP**: 76 (60, 85.75) | 78 (70.85) | 81 (75.25, 87) | 0.047 | – | 0.125 | 0.06 |
- **ΔSBP**: 10 (4, 14.25) | 2 (−4, 10) | 29 (17.5, 36.75) | 0.000 | 0.025 | 0.007 | <0.001 |
- **ΔDBP**: 0.5 (−1.75, 2.52) | −2 (−7.2) | 9 (0.25, 12) | 0.000 | 0.138 | 0.096 | <0.001 |

### Clinical laboratory assessment

- **RBC count, × 10¹²/µl**: 4.5 (4.3, 4.95) | 4.7 (4.4, 5) | 4.6 (4.2, 4.9) | 0.224 | – | – | – |
- **Hematuric, %**: 0.41 (0.37, 0.43) | 0.41 (0.39, 0.44) | 0.41 (0.38, 0.42) | 0.083 | – | – | – |
- **Hemoglobin, g/dl**: 143 (126, 149) | 142 (134, 150) | 141 (130, 150) | 0.579 | – | – | – |
- **Serum glucose, mg/dl**: 5.2 (5.1, 5.9) | 5.4 (5.6, 5.9) | 5.5 (5.2, 7.3) | 0.274 | – | – | – |
- **Serum sodium, mmol/L**: 141 (140.5, 142) | 140.0 (139, 142) | 141 (139, 142) | 0.193 | – | – | – |
- **Serum potassium, mmol/L**: 4.4 (4.15, 4.6) | 4.2 (4.4, 4.4) | 4.1 (3.9, 4.4) | 0.040 | 0.102 | 0.035 | 0.582 |
- **Serum chloride, mmol/L**: 103 (102, 104) | 103 (101, 104) | 103 (101, 105) | 0.738 | – | – | – |
- **Total protein, g/dl**: 68 (65, 70.5) | 70 (68, 73) | 69 (68, 71) | 0.004 | 0.007 | 0.382 | 0.456 |
- **Albumin, g/dl**: 40 (38, 41.5) | 41 (40, 43) | 40 (40, 42) | 0.052 | – | – | – |
- **Creatinine, mg/dl**: 88 (76, 97) | 80 (71, 92.25) | 80 (71, 101) | 0.461 | – | – | – |
- **Urea nitrogen, mg/dl**: 6.5 (5.95, 7.7) | 6 (5, 7.1) | 6.8 (5.7, 7.9) | 0.008 | 0.081 | 1 | 0.071 |
- **Serum uric acid, mg/dl**: 339 (306, 378) | 299 (250, 357) | 303 (268, 345) | 0.055 | – | – | – |

*BMI, body mass index; DBP, diastolic blood pressure; HY, Hoehn and Yahr staging; LEDD, levodopa equivalent daily dose; MOCA, Montreal Cognitive Assessment; OH, orthostatic hypotension; PIGD, postural instability and gait disorders; RBDSQ, rapid eye movement sleep behavior disorder screening questionnaire; SBP, systolic blood pressure; TD, tremor dominant; MDS-UPDRS, Movement Disorders Society Unified Parkinson’s Disease Rating Scale; UPSIT, University of Pennsylvania Smell Identification Test; ΔSBP, orthostatic DBP change; ΔSBP, orthostatic SBP change.

These values represent the medians, with the interquartile range in parentheses or the number of patients, with percentages in parentheses. All significant p-values are highlighted by bold characters.
Our results show the differences in OH trajectories of patients with PD and in particular highlight those that are worth clinical attention, especially male patients with PD and lower supine DBP and lower total proteins. These patients tend to develop OH and are more prone to falls. As such, this patient group may greatly benefit from an early management strategy that includes advice such as changing positions slowly, particularly upon standing.

In previous studies, there are contradictory results about the association between disease duration and OH. Wüllner et al. (2007) revealed a significant correlation of OH and clinical course through logistic regression analyses. Li et al. (2019) found a difference in disease duration between patients with PD with or without OH; however, disease duration was not found to be a statistically significant influencing factor in PD-OH, with a p-value of 0.718 in further logistic regression. In a longitudinal study conducted by Jost and Augustin (2015), there was a lack of a correlation between the severity of OH in PD and disease duration. Nevertheless, in clinical practice, a subset of patients will develop OH during the course of PD. Our findings indicate that, for the majority of patients with PD, ΔSBP remains stable over the disease course. However, in 2.7% of patients, there was a rapidly increasing ΔSBP over the disease course, which may be very difficult to detect in an analysis of the total population.

Clinical variables have been shown to play different roles in cross-sectional studies of PD-OH, as well as in the longitudinal trajectory of PD-OH. In the previous studies, PD-OH has been significantly related to older age, lower body mass index (BMI), more severe motor symptoms, higher LEDD, and higher blood glucose (Perez-Lloret et al., 2012; Nakamura et al., 2017; Li et al., 2019). Similarly, our results showed that older patients with higher MDS-UPDRS-III scores, indicating severe motor symptoms, tend to have higher ΔSBP. In Nakamura et al. (2017), it was emphasized that weight, rather than height, drove the association between BMI and OH. In contrast, however, we found the height of Class 2 to be significantly shorter than that of Class 1 and Class 3, and no association of weight or BMI with OH was identified. Campese et al. (2021) also reported a negative association between classic OH and shorter stature in male patients with PD and considered that the non-neurogenic mechanisms may prevent shorter individuals from BP declines on standing. Considering that some PD medication may be risk factors for OH, we compared the baseline LEDD and the average LEDD during follow-up years among the three classes. No significant difference was found between groups, indicating that LEDD does not change the natural trajectory of ΔSBP. In addition, non-motor scores, BP at baseline, and some laboratory parameters were also different among classes. For example, the patients in the high-stable class had more severe RBD and olfactory dysfunction than those in the low-stable class.

It seemed that some patients with PD had remarkable non-motor symptoms at the early stage of PD, indicating the presence of a particular internal phenotypic cluster. It was reported that the combination of olfactory dysfunction, OH, and RBD was associated with a malignant phenotype of PD characterized by more rapid progression of cognitive deficits and postural instability, which could result from the pathological expansion of PD from the olfactory pathway and along fiber tracts in the brain stem simultaneously (Pilotto et al., 2019; Nomura et al., 2020). In PD, gender is significantly related to multiple motor and non-motor symptoms. In some previous studies, no correlations were identified between OH and gender in patients with PD (Wüllner et al., 2007; Bae et al., 2011). OH was reported for 10% of women and 11% of men in Wüllner et al. (2007), without significant correlation of OH with gender through logistic regression. In contrast, Velseboer et al. (2017) found male sex was associated with the presence of OH in PD. We also found that male sex was one of the predictors of increasing ΔSBP. This finding in patients with PD is distinct relative to the general population, where it is reported that the incidence of OH is higher in women than men (Fedorowski et al., 2009), due to higher estrogen levels, a more active parasympathetic system, lower

### Table 1

| Variable          | Odds ratio (95% CI) | P value |
|-------------------|--------------------|---------|
| Male              | 4.687 (1.024-21.459) | 0.047   |
| Supine SBP        | 1.035 (1.000-1.072)  | 0.052   |
| Supine DBP        | 0.934 (0.876-0.996)  | 0.036   |
| ΔDBP              | 1.067 (0.995-1.143)  | 0.067   |
| Total protein     | 0.812 (0.700-0.941)  | 0.006   |
| Serum potassium   | 3.730 (0.870-15.995) | 0.076   |

FIGURE 2 | Odds ratios (OR) and 95% confidence interval (CI) of predictor variables on increasing orthostatic change of systolic blood pressure (ΔSBP) trajectory.
Our results show that total protein was one of the predictors in peripheral vasoconstriction, which further causes systolic OH. Malnutrition may lead to a reduction in muscle mass and the risk of OH. Malnutrition is also an important risk factor for OH (Kocyigit et al., 2018). Furthermore, both malnutrition and use of many other drugs except for PD medication related to OH were not included in the analysis. Second, there were many other drugs except for PD medication related to OH not included in the analysis. Third, the participants in PPMI were mostly patients with de novo PD with short follow-up durations, so, the data for late-stage PD was insufficient. Fourth, the conditions for BP measurement were not rigorously defined. For example, room temperature during BP measurement was not uniform across different centers. Fifth, supine BP was measured after 1–3 min of quiet rest, which was shorter than the standard procedure requirement of 5 min (Lahrmann et al., 2006). Inadequate rest may affect the point measurements but influence the trajectory analysis mildly.

CONCLUSION

This study provides new information on the longitudinal development of ΔSBP in patients with PD with distinct trajectories of rapidly increasing, low-stable, and high-stable class. Male sex, lower supine DBP, and lower total proteins helped to identify the class with increasing risk for OH. Further research is needed to discover the biological mechanisms that explain these subgroups and guide future preventive interventions for OH.

DATA AVAILABILITY STATEMENT

Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-dataspecimens/download-data). For up-to-date information on the study, visit ppmi-info.org.

ETHICS STATEMENT

Each participating PPMI site received ethical approval before study initiation and written informed consent was obtained from all participants.

AUTHOR CONTRIBUTIONS

KC and YaZ designed the study. KC and KD collected the data. KD and YiZ performed the statistical analysis. KC and YG analyzed the results and drafted the manuscript. All authors contributed to the manuscript revision and read and approved the submitted version.

FUNDING

PPMI—a public–private partnership—was funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including AbbVie, AcureX Therapeutics, Allergan, Amathus Therapeutics, Avid Radiopharmaceuticals, Bial Biotech, Biogen, BioLegend, Bristol-Myers Squibb, Calico, Celgene, Denali Therapeutics, 4D Pharma PLC, GE Healthcare, Genentech, GSK GlaxoSmithKline, Golub Capital, Handl Therapeutics, insitro, Jannsen Neuroscience, Lilly, Lunbeck, Merck & Co., MSD Meso Scale Discovery, Neurocrine, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanoﬁ Genzyme, Servier, Takeda, Teva, UCB, Verily, Voyager Therapeutics, and Yumanity Therapeutics. This project was funded by the National Natural Science Foundation of China (Grant No. 82001345).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnagi.2021.762759/full#supplementary-material.
REFERENCES

Bae, H. J., Cheon, S. M., and Kim, J. W. (2011). Orthostatic hypotension in drug-naïve patients with Parkinson’s disease. J. Mov. Disord. 4, 33–37. doi: 10.14802/jmd.11005

Campese, N., Goebel, G., Leys, F., Ndayisaba, J. P., Eschibocek, S., Eckhardt, C., et al. (2021). Orthostatic hypotension in parkinson’s disease: do height and weight matter? Mov. Disord. 36, 2703–2705. doi: 10.1002/mds.28768

Cheng, Y. C., Vyas, A., Hymen, E., and Perlmutter, L. C. (2011). Gender differences in orthostatic hypotension. Am. J. Med. Sci. 342, 221–225. doi: 10.1097/MAJ.0b013e318208752b

Fedorowski, A., Burri, P., and Melander, O. (2009). Orthostatic hypotension in genetically related hypertensive and normotensive individuals. J. Hypertens. 27, 976–982. doi: 10.1097/HJH.0b013e3283279860

Fedorowski, A., Hamrefova, V., Sutton, R., van Dijk, J. G., Freeman, R., Lenders, J. W., et al. (2017). Do we need to evaluate diastolic blood pressure in patients with suspected orthostatic hypotension? Clin. Auton. Res. 27, 167–173. doi: 10.1007/s10286-017-0409-7

Fedorowski, A., Wahlstrand, B., Hedner, T., and Melander, O. (2014). Systolic and diastolic component of orthostatic hypotension and cardiovascular events in hypertensive patients: the Captopril prevention project. J. Hypertens. 32, 75–81. doi: 10.1097/HJH.0b013e32836cd59

Freeman, R., Wieling, W. A., Axelrod, F. B., Benditt, D. G., Benarroch, E., Biaggioni, I., et al. (2011). Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin. Auton. Res. 21, 69–72. doi: 10.1007/s10286-011-0119-5

Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez-Martin, P., et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129–2170. doi: 10.1002/mds.23240

Hiroth, Y. H., Pedersen, K. F., Dalen, I., Tynsnes, O. B., and Alves, G. (2019). Orthostatic hypotension in Parkinson disease: a 7-year prospective population-based study. Neurology 93, e1526–e1534. doi: 10.1212/wnl.0000000000008314

Hoehn, M. M., and Yahr, M. D. (1967). Parkinsonism: onset, progression and mortality. Neurology 17, 427–442. doi: 10.1212/wnl.17.5.427

Hommel, A., Faber, M. J., Weerkamp, N. J., van Dijk, J. G., Bloem, B. R., and Koopmans, R. T. (2016). Prevalence and prescribed treatments of orthostatic hypotension in institutionalized patients with parkinson’s disease. J. Parkinsons Dis. 6, 805–810. doi: 10.3233/jpd-160853

Jost, W. H., and Augustis, S. (2015). Severity of orthostatic hypotension in the course of Parkinson’s disease: no correlation with the duration of the disease. Parkinsonism Relat. Disord. 21, 314–316. doi: 10.1016/j.parkreldis.2014.12.016

Kocigj, S. E., Ates Bulut, E. A. P., Aydin, A. E., and Isik, A. T. P. (2021). Improvement of nutritional status enhances cognitive and physical functions in older adults with orthostatic hypotension. Nutrition 90:111261. doi: 10.1016/j.nut.2021.111261

Kocigj, S. E., Soysal, P., Ates Bulut, E., and Isik, A. T. (2018). Malnutrition and malnutrition risk can be associated with systolic orthostatic hypotension in older adults. J. Nutr. Health Aging 22, 928–933. doi: 10.1016/j.sna.2018-1032-6

Lagro, J., Laurensen, N. C., Schalk, B. W., Schoon, Y., Claassen, J. A., and Olde Rikkert, M. G. (2012). Diastolic blood pressure drop after standing as a clinical sign for increased mortality in older falls clinic patients. J. Hypertens. 30, 1195–1202. doi: 10.1097/HJH.0b013e328352596f

Lahrmann, H., Cortelli, P., Hilt, M., Mathias, C. J., Struhal, W., and Tassinari, M. (2006). EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur. J. Neurol. 13, 930–936. doi: 10.1111/j.1468-1331.2006.01512.x

Li, L., Guo, P., Ding, D., Lian, T., Zuo, L., Du, F., et al. (2019). Parkinson’s disease with orthostatic hypotension: analyses of clinical characteristics and influencing factors. Neurol. Res. 41, 734–741. doi: 10.1007/s12633-019-1012-0

Logan, B., Gaudreau, P., Thompson, A., Ca Rraro, N., and Andruﬀ, H. (2009). Latent class growth modelling: a tutorial. Tutor. Quant. Methods Psychol. 5, 11–24.
scale: comparison with the unified Parkinson’s disease rating scale. Mov. Disord. 28, 668–670. doi: 10.1002/mds.25383
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., and Clarke, C. E. (2010). Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord. 25, 2649–2653. doi: 10.1002/mds.23429
Velseboer, D. C., de Haan, R. J., Post, B., Kreidieh, C., Verberne, H. J., and de Bie, R. M. A. (2017). Orthostatic hypotension in Parkinson’s disease: the relation of blood pressure tests and symptoms in daily life. Mov. Disord. Clin. Pract. 4, 329–334. doi: 10.1002/mdc3.12415
Wüllner, U., Schmitz-Hübsch, T., Antony, G., Fimmers, R., Spottke, A., Oertel, W. H., et al. (2007). Autonomic dysfunction in 3414 Parkinson’s disease patients enrolled in the German network on Parkinson’s disease (KNP e.V.): the effect of ageing. Eur. J. Neurol. 14, 1405–1408. doi: 10.1111/j.1468-1331.2007.01982.x
Yang, T., Zhan, Z., Zhang, L., Zhu, J., Liu, Y., Zhang, L., et al. (2020). Prevalence and risk factors for malnutrition in patients with Parkinson’s disease. Front. Neurol. 11:533731. doi: 10.3389/fneur.2020.533731

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Chen, Du, Zhao, Gu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.